@article{3090789,
    title = "Bevacizumab may be active in myelofibrosis",
    author = "Nikolaidis, I. and Makrilia, N. and Xyla, V. and Dilana, K. and Stathopoulos, D. and Meletis, I. and Syrigos, K.",
    journal = "Cancer Investigation",
    year = "2010",
    volume = "28",
    number = "1",
    pages = "111-112",
    issn = "0735-7907, 1532-4192",
    doi = "10.3109/07357900902918502",
    keywords = "bevacizumab;  hydroxyurea, aged;  article;  bone marrow biopsy;  case report;  coughing;  drug dose reduction;  drug effect;  drug response;  dyspnea;  epistaxis;  female;  heart tamponade;  human;  human tissue;  leukocyte count;  leukocytosis;  lung adenocarcinoma;  lung biopsy;  lung non small cell cancer;  monotherapy;  myeloid metaplasia;  myeloproliferative disorder;  priority journal;  treatment outcome;  weight reduction, Aged;  Angiogenesis Inhibitors;  Antibodies, Monoclonal;  Carcinoma, Non-Small-Cell Lung;  Drug Administration Schedule;  Female;  Humans;  Hydroxyurea;  Infusions, Parenteral;  Leukocyte Count;  Lung Neoplasms;  Primary Myelofibrosis;  Treatment Outcome",
    abstract = "A case of a 69-year-old woman with myelofibrosis presenting with non-small cell lung cancer was reported at Sotiria General Hospital in Athens. She was administered bevacizumab infusions biweekly and a great decrease in the number of her white blood cells was observed. Such low levels of white blood cells had never been reached in the past, when she was receiving hydroxyurea."
}